We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Cartridge-based administration using injection device systems has dominated the insulin market for many years. In 2011, the insulin market for cartridge-based container closure systems was at an estimated 1 billion units. Additional applications for cartridge-based container systems include dental, at more than 450 million units per year, and therapies such as human growth hormone, interferon and epinephrine. In fact, thanks to lower production costs when compared to vial and syringe systems, cartridge-based delivery has found a widespread and growing market.
As the healthcare market continues to evolve and administration in the home care setting increases, cartridge-based delivery has made inroads into a variety of markets. Today, systems are in use or are under consideration for use with such therapeutic categories as anemia, rheumatoid arthritis, dermatology, oncology and hepatitis. In addition, insulin use is increasing due to the growth in population and higher demand in emerging countries, so the diabetes care market is evolving to provide more accurate and reproducible dosing. Insulin pen injectors, which commonly employ a 3.0mL cartridge, provide convenience and ease of use to patients, which may in turn help to improve patient compliance.
As the global market moves toward home-based care and multi-dose delivery systems for select therapeutic categories, pharmaceutical manufacturers are now seeking sterile components, including cartridges, plungers and other high-quality components, that are capable of offering ready-to-use quality and high functional performance in a variety of delivery systems and devices. Such quality is essential to the functionality, safety and efficacy of pens, injection devices and cartridge-based delivery systems.
West offers high-quality, ready-to-use cartridge components. Our industry-proven Westar® component processing reduces the risk of variability and its potential effects on drug quality, safety and efficacy.
The market for prefillable syringe systems (PFS) is growing at a rate of approximately 10 percent per year, with cartridge-based systems growing even faster at rates of 13 percent (2013 market outlook, IMS). The predominant areas of growth are within the insulin and biologics therapeutic areas, as well as overall growth within emerging markets.
Drug delivery via cartridge-based systems has been around for many years, with traditional applications being for the dental and insulin markets. These traditional markets will continue to maintain much of the volume for cartridge-based systems in the future; however, there is an increasing trend toward other therapeutic classes of drugs, such as those that treat auto-immune diseases, that never used cartridges before. This trend, along with the projected growth in the insulin market, indicates substantial overall growth in the cartridge space over the next several years. This Blog discusses the issues driving these trends and the West product portfolio in the cartridge market.
West is excited to announce an addition to its NovaPure<sup>®</sup> product line — NovaPure 3mL Cartridge components, which include plunger and seal components specifically designed to ensure consistency of delivery for higher-volume injectable drug delivery systems. The components were designed to address specific issues and challenges the pharmaceutical industry faces in bringing innovative injectable drug products to market.
Component processing is a source of risk and variability, especially for loose particulate and silicone oil that can compromise quality, putting patients at risk. To simplify drug development and streamline manufacturing, pharmaceutical companies can select cartridge plungers and lined seals in a ready-to-use format.
On November 14, World Diabetes Day will be observed around the globe. Diabetes is a growing issue, with more than 415 million adults living with the disease, a number that is expected to increase to 642 million – or 1 in 10 adults – by 2040.
English
Chinese
